The mission of the second edition of the European Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections, EU European Union (European Union )-JAMRAI2 is to lead the fight against antimicrobial resistance (AMR) through joint and coordinated action across Europe. It builds on the success of its first edition (2017-2021).

Goals

EU-JAMRAI2 aims to transform the world’s approach to antimicrobial resistance through a One Health perspective. EU-JAMRAI envisions a European community where prevention, early detection, and effective management of antimicrobial resistance are key priorities at all levels of healthcare, from primary care to hospital settings and beyond.

Consortium

More than 120 partners from 30 countries, supported by approximately 40 stakeholders, are actively engaged in EU-JAMRAI-2. European institutions such as ECDC and EFSA, alongside global bodies such as WHO, WOAH, OECD, UNEP, and FAO, contribute their expertise to enrich discussions and ensure alignment with existing initiatives. Furthermore, human, animal, and environmental health professionals and patient representatives play integral roles in this collective effort.

The overall objectives of the project are to:

• Provide direct and sizeable support to help member states in the development and the update of their National Action Plans on AMR
• Support the wider uptake of state-of-the-art IPC for both community-acquired and healthcare associated infection as well as AMS strategies
• Strengthen surveillance and coordination between the animal, human and environmental domains to protect people and animals from AMR 
• Increase awareness and understanding of AMR across Europe
• Promote the One Health approach
• Make Europe a best-practice region

RIVM role

RIVM has a leading role in two work packages in the environmental domain. The aims are to identify a common approach towards environmental AMR surveillance in Europe, to develop a new European network for bringing together countries and experts in environmental surveillance; EARS-Env, and to do a scoping study into the feasibility of collection of usage data of disinfectants and fungicides. Moreover, we aim to map, across Europe, interventions that reduce emissions of AMR from animal and human activities to the environment and determine best practices. 

For these activities, work package task leaders from RIVM are Heike Schmitt, Mark Montforts and Roosmarijn Luiken.

RIVM is also active as a member in several other work packages and will work, also through JAMRAI, on the following objectives:

• Strengthen the national AMR surveillance system in the human sector, including the legal and information security aspects.
• Determine the added value of integrated analysis of AMR surveillance data and take further steps in integrated surveillance and national One Health reporting. 
• Promote professional empowerment and networking for antimicrobial stewardship in hospitals, primary care, and long-term care facilities. 
• Supporting the Dutch Ministry of Health, Welfare and Sport in their work within EU-JAMRAI2 on supporting member countries in implementing and updating their One Health strategies in the National Action Plans against AMR. 

Roosmarijn Luiken coordinates RIVM’s activities for EU-JAMRAI2. Other RIVM colleagues involved include Ana Maria de Roda Husman, Annelot Schoffelen, Carolien Ruesen, Guusje Jacobs, Heike Schmitt, Hetty Blaak, Jorrit Kabel, Karuna Vendrik, Mark Montforts, Rob Mariman, Sabine de Greeff and Samira Koullali.

Funding

EU-JAMRAI2 receives funding from the European union’s EU4Health programme under grant agreement No 101127787.